MDMA-assisted therapy shows promise for long-term depression relief

MDMA-assisted therapy shows preliminary evidence of lasting benefit for people with major depressive disorder (MDD), with improvements that persisted for months after treatment. The Norway-based, small open-label study enrolled 12 adults with at least moderate MDD severity. Participants received two MDMA dosing sessions about one month apart (80 mg plus 40 mg, then 120 mg plus 60 mg), integrated with a structured psychotherapy course that included preparation and integration sessions. Depression severity was tracked using clinician-rated measures such as the Montgomery-Asberg Depression Rating Scale, with follow-up occurring about seven months after the study began. Results reported sustained response and remission for many participants at the seven-month point, along with reductions in functional impairment and generalized anxiety and improvements in sleep quality. Safety monitoring included suicidal ideation and behavior assessments; no serious suicidal behavior occurred, though some participants reported increased suicidal thoughts at follow-up. The findings were limited by the small sample size and lack of a control group, so the article emphasizes the need for larger randomized controlled trials and careful clinical safeguards rather than viewing MDMA as a standalone antidepressant.